LOS ANGELES--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) today criticized HIV/AIDS drug maker Gilead Sciences Inc. for pulling funding support from the organization’s global programs in response to AHF’s advocacy efforts. For the past year AHF has spearheaded public advocacy campaigns challenging Gilead on its drug pricing policies, as well as the company’s push for approval from the U.S. Food and Drug Administration (FDA) for a new use for its HIV/AIDS treatment drug Truvada, as an HIV “prevention” pill—or pre-exposure prophylaxis (PrEP). Despite Gilead’s history of consistent—and progressively increasing—funding support for AHF’s global programs, the nonprofit was told by a company representative recently that it will not be receiving Gilead funding support this year.
